# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
1 | 03-21-2024 | 12-31-2023 | 10-K | |
2 | 11-09-2023 | 09-30-2023 | 10-Q |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Autolus Therapeutics plc (NASDAQ:AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...
Needham analyst Gil Blum reiterates Autolus Therapeutics (NASDAQ:AUTL) with a Buy and maintains $9 price target.
Truist Securities analyst Gil Blum maintains Autolus Therapeutics (NASDAQ:AUTL) with a Buy and raises the price target from ...
S-3ASR